Navigation Links
EpiCept Reports Regulatory Progress on Ceplene(TM)
Date:9/17/2007

ong term after relapse. There are currently no proven treatments for maintaining long-term remission for AML patients.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Increasing unnecessary regulations on drug plans could inflict higher ... medications through a managed drug plan, according to a ... Analysis Senior Fellow Devon Herrick. "The ... helps makes medications affordable," says Herrick. "Blatant protectionism through ... protections, but more often than not they are designed ...
(Date:4/20/2015)... -- Stand Up To Cancer (SU2C) and the American Cancer ... Team to attack the number one cancer killer in America, ... American Association for Cancer Research (AACR), Scientific Partner to SU2C. ... the United States will be diagnosed with ... from it, making lung cancer the leading cause of cancer ...
(Date:4/20/2015)... April 20, 2015 Eli Lilly and Company ... medicine ixekizumab was statistically superior to placebo in the ... demonstrated by the proportion of patients achieving an ACR ... represents a 20 percent reduction in disease signs and ... response criteria. During the 24-week, Phase 3 study, titled ...
Breaking Medicine Technology:Restrictive Drug Plan Regulations Will Hurt Patients 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... Richard Merkin, President and CEO of Heritage Provider Network, announced ... Health Prize, the world,s largest predictive modeling contest. ... Data 2.0 Conference in San Francisco, Dr. Merkin challenged innovators ... the $3 million prize saying, "We have an opportunity to ...
... Reportlinker.com announces that a new market research report ... Drug Delivery in Cancer - technologies, markets and ... Drug delivery remains a challenge in management ... cancer are being diagnosed worldwide each year and ...
Cached Medicine Technology:Heritage Provider Network Announces the Official Launch of the $3 million Dollar Heritage Health Prize 2Heritage Provider Network Announces the Official Launch of the $3 million Dollar Heritage Health Prize 3Reportlinker Adds Drug Delivery in Cancer - technologies, markets and companies 2Reportlinker Adds Drug Delivery in Cancer - technologies, markets and companies 3
(Date:4/21/2015)... Invictus Medical has secured the ... for a second innovative technology aimed at making ... newborn infants’ cognitive development. , “This technology addresses ... have identified through extensive interviews and input from ... Invictus Medical’s Chief Technology Officer. “We believe this ...
(Date:4/20/2015)... Bradley, Illinois (PRWEB) April 20, 2015 ... community, will host an Open House and Dine-and-Dash Spaghetti ... 22. , The community, which is located in Centralia, ... and rental homes for low-income adults 55 and older. ... speak with staff about supportive living options for seniors. ...
(Date:4/20/2015)... (PRWEB) April 21, 2015 Reality show ... and girlfriends at the twentieth annual Michigan International Women’s ... in Novi. , “There is lots to see and ... to shopping for fashion and gifts,” said Beth Anderson, ... are entertaining and encouraging with appearances from Randy Fenoli ...
(Date:4/20/2015)... The partners of Urgent Care of Westchester and Riverdale Urgent ... Spa with a special event. Residents of Westchester County are ... on April 24 on 909 Midland Ave. in Yonkers, NY. ... also get the chance to win free services from a ... as well as up to 40 percent discounts on skin ...
(Date:4/20/2015)... Florida (PRWEB) April 20, 2015 The ... Academy for Quality and Safety Improvement as the 2015 ... presented at the association’s Annual Meeting, April 18, in ... work as a team, patient safety can be dramatically ... association's president and CEO. “Northwestern Medicine and its Academy ...
Breaking Medicine News(10 mins):Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 2Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 3Health News:Bella Diosa Says Hello to Yonkers Community with Spa Party 2Health News:2015 Leape Ahead Award honors Northwestern Medicine’s Academy for Quality and Safety Improvement 2Health News:2015 Leape Ahead Award honors Northwestern Medicine’s Academy for Quality and Safety Improvement 3
... magnetic resonance, or SSNMR, is a valuable tool ... proteins and other biomolecules. But the imaging process ... isotope-labeled sample for study. , Yoshitaka Ishii, associate ... at Chicago, believes he has found a quicker ...
... outing, like going to the beach, boosts well-being, study ... Although everyone knows that money can,t buy happiness, purchasing ... well-being, new research suggests. , In a study that ... a recent purchase intended to make them happy, researchers ...
... IV formulation of clopidogrel, the active ingredient in ... PRUSSIA, Pa., Feb. 9 Prism Pharmaceuticals ... of PM103, a novel intravenous formulation of clopidogrel bisulfate ... poster presentation at the 58th Scientific Session of the ...
... the maker of TrackWise(R) and the market, ... software, is pleased to announce its forthcoming webinar:, ... a free Webinar scheduled to "go live" on Tuesday, ... p.m. EST., Due to the ...
... Kronos Science Laboratories (KSL) has lost a great leader and a ... 2009 after a stormy three month battle with an aggressive cancer ... a superb laboratory scientist. He completed a BA at the ... Psychology in 1972, and then stayed on an additional year to ...
... BAY, Wis., Feb. 9 Shopko announced today that ... Store of the Year design,competition for the design of ... last year. Shopko,s new store design will be profiled ... The annual competition celebrates retail design across all industry,segments. ...
Cached Medicine News:Health News:New technique boosts protein NMR imaging speeds 2Health News:Experiences Bring More Joy Than Possessions Do 2Health News:Experiences Bring More Joy Than Possessions Do 3Health News:Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology 2Health News:Sparta Systems to Address Critical Electronic Medical Device Reporting (eMDR) Concerns with Free Webinar 2Health News:Sparta Systems to Address Critical Electronic Medical Device Reporting (eMDR) Concerns with Free Webinar 3Health News:Kronos Science Laboratories (KSL) Has Lost a Great Leader and a Good Friend, Dr. Chris Heward 2Health News:New Shopko Store Design Takes Top Honors 2Health News:New Shopko Store Design Takes Top Honors 3
... to use and transportable, the Dornier Compact Delta ... user and the patient. The systems shock source ... zone accuracy and avoid the risk of misalignment. ... unique due to its motorized lateral and horizontal ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: